Skip Ribbon Commands Skip to main content
A. Karim Kader, MD, PhD

A. Karim Kader, MD, PhD

Minimally Invasive Surgery; Urology

 

Contact Information

858-822-7874
jmthompson@ucsd.edu



View clinical profile


Dr. A. Karim Kader is one of the most experienced surgeons in the United States performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He received his undergraduate, doctorate of philosophy, and medical degrees from the University of British Columbia and completed his urology residency at the University of Toronto. He completed a urologic oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Kader holds several patents for genetic discoveries that hold significant promise for early detection and prevention of prostate cancer. He is the principal investigator for numerous clinical research projects and has published extensively. His research interests include genetic markers of risk and outcome in urologic cancer.

Publications

  • Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK. Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol. 2013;27:1046-50. PMID: 23517015
  • Liss MA, Kader AK. Robotic-assisted laparoscopic radical cystectomy: history, techniques and outcomes. World J Urol. 2013;31:489-97.PMID:23512230
  • Kader AK, Sun J, Reck BH, Newcombe PJ, Kim S-T, Hsu F-C, D'Agostino Jr. RB, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Following an Initial Negative Biopsy: Findings from the REDUCE Trial. Eur Urol. 2012;62(6):953-61; PMID: 22652152 Abstract | Full Text

Print